Skip to main content

Table 2 Association between vaccination and mumps complications or hospitalization, vaccine effectiveness, Czech Republic, 2007–2012

From: Protective effect of vaccination against mumps complications, Czech Republic, 2007–2012

Type of complication

VACCINATION number of dosesb

MUMPS number of cases

COMPLICATIONS number of cases (%)

Unadjusted odds ratio (95 % CI)

Adjustedc odds ratio (95 % CI)

P value

Adjustedc vaccine effectiveness % (95 % CI)

Any complication

0

1662

430 (25.9)

Ref

Ref

  
 

1

71

4 (5.6)

0.17 (0.06, 0.47)

0.32 (0.11, 0.91)

0.033

68 (9, 89)

 

2

7907

516 (6.5)

0.20 (0.17, 0.23)

0.32 (0.25, 0.39)

<0.001

68 (61, 75)

Orchitisa

0

1006

322 (32.0)

Ref

Ref

  
 

1

33

3 (9.1)

0.21 (0.06, 0.70)

0.34 (0.10, 1.16)

0.086

66 (-16, 10)

 

2

4548

333 (7.3)

0.17 (0.14, 0.20)

0.28 (0.22, 0.36)

<0.001

72 (64, 78)

Meningitis

0

1662

66 (4.0)

Ref

Ref

  
 

1

71

1 (1.4)

0.35 (0.05, 2.52)

0.50 (0.07, 3.80)

0.502

50 (-280, 93)

 

2

7907

87 (1.1)

0.27 (0.19, 0.37)

0.34 (0.21, 0.54)

<0.001

64 (46, 79)

Encephalitis

0

1662

12 (0.7)

Ref

Ref

  
 

1

71

0 (0.0)

    
 

2

7907

3 (0.0)

0.05 (0.01, 0.19)

0.07 (0.02, 0.34)

0.001

93 (66, 98)

Pancreatitis

0

1662

15 (0.9)

Ref

Ref

  
 

1

71

0 (0.0)

    
 

2

7907

47 (0.6)

0.66 (0.37, 1.18)

1.18 (0.49, 2.86)

0.706

-18 (-186, 51)

Hospitalization

0

1662

511 (30.7)

Ref

Ref

  

(males + females)

1

71

6 (8.5)

0.21 (0.09, 0.48)

0.32 (0.13, 0.76)

0.010

68 (24, 87)

 

2

7907

673 (8.5)

0.21 (0.18, 0.24)

0.29 (0.24, 0.35)

<0.001

71 (65, 76)

Hospitalization

0

1006

417 (41.5)

Ref

Ref

  

(males onlya)

1

33

4 (12.1)

0.19 (0.07, 0.56)

0.30 (0.10, 0.89)

0.030

41 (11, 90)

 

2

4548

502 (11.0)

0.18 (0.15, 0.20)

0.26 (0.21, 0.33)

<0.001

74 (67, 79)

  1. Note
  2. Ref - reference category (unvaccinated)
  3. aonly males, of 5587 males
  4. b23 cases (13 in males and 10 in females) in three-dose vaccine recipients were not included in the analysis
  5. cadjusted for age, gender, year of onset, and region (NUTS3)